{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T21:00:30Z","timestamp":1777064430815,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fixed-dose combinations (FDCs) for blood pressure control can simplify prescribing, improve medication adherence, and be cost-effective. In Japan, real-world data about the class effects of antihypertensive drugs on medication adherence are limited. Using the nationwide database of medical health claims from Diagnosis Procedure Combination hospitals, treatment patterns and adherence were analyzed for 47,891 patients prescribed antihypertensive medication between April 2014 and March 2015. Adherence was assessed by the proportion of days covered (expressed as % PDC). Patients were prescribed a mean of 2.0\u2009\u00b1\u20091.0 antihypertensive drugs and 2.4\u2009\u00b1\u20091.7 pills for their index prescription. Mean adherence overall was 91.5% PDC and was inversely correlated with the number of antihypertensive drugs or pills prescribed on the index date. Mean % PDC was significantly higher (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) for CCB\u2009+\u2009ARB versus ARB\u2009+\u2009thiazide diuretic combinations and for CCB\u2009+\u2009ARB\u2009+\u2009\u03b2-blocker versus CCB\u2009+\u2009ARB\u2009+\u2009thiazide diuretic combinations. Adherence was significantly higher (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) for FDC (CCB\u2009+\u2009ARB) versus corresponding single-drug combinations, but not for other comparisons of FDCs versus single-drug combinations. On the other hand, FDCs were not always used effectively; specifically, FDCs were frequently used concomitantly with a single agent(s) from the same drug class(es) as the FDC. From the results of our study, no clear differences were observed in medication adherence according to the presence or absence of FDC formulations, and there were cases in which FDCs were not being utilized effectively to simplify prescribing.<\/jats:p>","DOI":"10.1038\/s41440-018-0127-0","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T03:28:33Z","timestamp":1542338913000},"page":"249-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment patterns and adherence to antihypertensive combination therapies in Japan using a claims database"],"prefix":"10.1038","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-3899","authenticated-orcid":false,"given":"Takayuki","family":"Ishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4281-0338","authenticated-orcid":false,"given":"Akinori","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0015-4793","authenticated-orcid":false,"given":"Shinzo","family":"Hiroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8425-5830","authenticated-orcid":false,"given":"Yukio","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Nishigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2412-1117","authenticated-orcid":false,"given":"Takuya","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"127_CR1","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1253\/circj.CJ-13-0847","volume":"77","author":"K Miura","year":"2013","unstructured":"Miura K, Nagai M, Ohkubo T. Epidemiology of hypertension in Japan: where are we now? Circ J. 2013;77:2226\u201331.","journal-title":"Circ J"},{"key":"127_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M et al. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253\u2013390.","journal-title":"Hypertens Res"},{"key":"127_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2796.2009.02084.x","volume":"266","author":"S Perreault","year":"2009","unstructured":"Perreault S, Dragomir A, White M, Lalonde L, Blais L, B\u00e9rard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266:207\u201318.","journal-title":"J Intern Med"},{"key":"127_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/HJH.0b013e328342ca97","volume":"29","author":"G Corrao","year":"2011","unstructured":"Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610\u201318.","journal-title":"J Hypertens"},{"key":"127_CR5","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/hr.2013.85","volume":"36","author":"S Shin","year":"2013","unstructured":"Shin S, Song H, Oh SK, Choi KE, Kim H, Jang S. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res. 2013;36:1000\u20135.","journal-title":"Hypertens Res"},{"key":"127_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1161\/STROKEAHA.108.522193","volume":"40","author":"FZ Kettani","year":"2009","unstructured":"Kettani FZ, Dragomir A, C\u00f4t\u00e9 R, Roy L, B\u00e9rard A, Blais L et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40:213\u201320.","journal-title":"Stroke"},{"key":"127_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jphs.12016","volume":"4","author":"DT Juarez","year":"2013","unstructured":"Juarez DT, Tan C, Davis J, Mau M. Factors affecting sustained medication adherence and its impact on health care utilization in patients with diabetes. J Pharm Health Serv Res. 2013;4:89\u201394.","journal-title":"J Pharm Health Serv Res"},{"key":"127_CR8","doi-asserted-by":"crossref","unstructured":"Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K.et al.Comfort Investigators. Impact of antihypertensive medication adherence on blood pressure control in hypertension: the COMFORT study. QJM. 2013;106:909\u201314..","DOI":"10.1093\/qjmed\/hct121"},{"key":"127_CR9","doi-asserted-by":"crossref","unstructured":"Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A.et al.UMPIRE Collaborative Group. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918\u201329..","DOI":"10.1001\/jama.2013.277064"},{"key":"127_CR10","doi-asserted-by":"publisher","first-page":"g3318","DOI":"10.1136\/bmj.g3318","volume":"348","author":"V Selak","year":"2014","unstructured":"Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318.","journal-title":"BMJ"},{"key":"127_CR11","doi-asserted-by":"crossref","unstructured":"Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S.et al.Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22:920\u201330..","DOI":"10.1177\/2047487314530382"},{"key":"127_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijcard.2014.11.176","volume":"181","author":"M Lafeber","year":"2015","unstructured":"Lafeber M, Grobbee DE, Schrover IM, Thom S, Webster R, Rodgers A et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2015;181:193\u20139.","journal-title":"Int J Cardiol"},{"key":"127_CR13","first-page":"CD009868","volume":"3","author":"E Bahiru","year":"2017","unstructured":"Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev. 2017;3:CD009868.","journal-title":"Cochrane Database Syst Rev"},{"key":"127_CR14","doi-asserted-by":"publisher","first-page":"e007111","DOI":"10.1136\/bmjopen-2014-007111","volume":"5","author":"V Becerra","year":"2015","unstructured":"Becerra V, Gracia A, Desai K, Abogunrin S, Brand S, Chapman R et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015;5:e007111.","journal-title":"BMJ Open"},{"key":"127_CR15","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1253\/circj.CJ-11-1481","volume":"76","author":"K Matsumura","year":"2012","unstructured":"Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K. et al.COMFORT Investigators. Does a combination pill of antihypertensive drugs improve medication adherence in Japanese? A randomized controlled trial. Circ J. 2012;76:1415\u201322.","journal-title":"Circ J"},{"key":"127_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/10641963.2015.1107086","volume":"38","author":"Y Kansui","year":"2016","unstructured":"Kansui Y, Ibaraki A, Goto K, Haga Y, Seki T, Takiguchi T et al. Trends in blood pressure control and medication use during 20 years in a hypertension clinic in Japan. Clin Exp Hypertens. 2016;38:299\u2013304.","journal-title":"Clin Exp Hypertens"},{"key":"127_CR17","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/hr.2016.96","volume":"39","author":"S Hiroi","year":"2016","unstructured":"Hiroi S, Shimasaki Y, Kikuchi T, Otsuka Y, Iwasaki K, Ohishi M. Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data. Hypertens Res. 2016;39:907\u201312.","journal-title":"Hypertens Res"},{"key":"127_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-015-0016-5","volume":"1","author":"S Tanaka","year":"2015","unstructured":"Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1:16.","journal-title":"J Pharm Health Care Sci"},{"key":"127_CR19","first-page":"110","volume":"59","author":"KB Ishikawa","year":"2016","unstructured":"Ishikawa KB. Medical big data for research use: current status and related issues. Jpn Med Assoc J. 2016;59:110\u2013124.","journal-title":"Jpn Med Assoc J"},{"key":"127_CR20","first-page":"255","volume":"22","author":"M Levi","year":"2016","unstructured":"Levi M, Pasqua A, Cricelli I, Cricelli C, Piccinni C, Parretti D et al. Patient adherence to olmesartan\/amlodipine combinations: fixed versus extemporaneous combinations. J Manag Care Spec Pharm. 2016;22:255\u201362.","journal-title":"J Manag Care Spec Pharm"},{"key":"127_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.02.001","volume":"21","author":"GL Colombo","year":"2016","unstructured":"Colombo GL, Agabiti-Rosei E, Margonato A, Mencacci C, Montecucco CM, Trevisan R et al. Impact of substitution among generic drugs on persistence and adherence: a retrospective claims data study from 2 local healthcare units in the Lombardy Region of Italy. Atheroscler Suppl. 2016;21:1\u20138.","journal-title":"Atheroscler Suppl"},{"key":"127_CR22","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296\u2013310.","journal-title":"Clin Ther"},{"key":"127_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/ijcp.12591","volume":"69","author":"CI Hsu","year":"2015","unstructured":"Hsu CI, Hsiao FY, Wu FL, Shen LJ. Adherence and medication utilisation patterns of fixed-dose and free combination of angiotensin receptor blocker\/thiazide diuretics among newly diagnosed hypertensive patients: a population-based cohort study. Int J Clin Pract. 2015;69:729\u201337.","journal-title":"Int J Clin Pract"},{"key":"127_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487\u201397.","journal-title":"N Engl J Med"},{"key":"127_CR25","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1161\/CIRCULATIONAHA.110.983874","volume":"123","author":"IM Kronish","year":"2011","unstructured":"Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123:1611\u201321.","journal-title":"Circulation"},{"key":"127_CR26","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/hr.2017.56","volume":"40","author":"S Tani","year":"2017","unstructured":"Tani S, Asayama K, Oiwa K, Harasawa S, Okubo K, Takahashi A et al. The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension. Hypertens Res. 2017;40:892\u20138.","journal-title":"Hypertens Res"},{"key":"127_CR27","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1097\/HJH.0000000000000222","volume":"32","author":"G Mancia","year":"2014","unstructured":"Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens. 2014;32:1708\u201315.","journal-title":"J Hypertens"},{"key":"127_CR28","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ijcard.2016.06.263","volume":"220","author":"M Schulz","year":"2016","unstructured":"Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE et al. Medication adherence and persistence according to different antihypertensive drug classes: a retrospective cohort study of 255,500 patients. Int J Cardiol. 2016;220:668\u201376.","journal-title":"Int J Cardiol"},{"key":"127_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","volume":"55","author":"AK Gupta","year":"2010","unstructured":"Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399\u2013407.","journal-title":"Hypertension"},{"key":"127_CR30","first-page":"255","volume":"22","author":"M Levi","year":"2016","unstructured":"Levi M, Pasqua A, Cricelli I, Cricelli C, Piccinni C, Parretti D et al. Patient adherence to olmesartan\/amlodipine combinations: fixed versus extemporaneous combinations. patient adherence to olmesartan\/amlodipine combinations: fixed versus extemporaneous combinations. J Manag Care Spec Pharm. 2016;22:255\u201362.","journal-title":"J Manag Care Spec Pharm"},{"key":"127_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40261-014-0188-z","volume":"34","author":"P Bramlage","year":"2014","unstructured":"Bramlage P, Ketelhut R, Fronk EM, Wolf WP, Smolnik R, Zemmrich C et al. Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. Clin Drug Investig. 2014;34:403\u201311.","journal-title":"Clin Drug Investig"},{"key":"127_CR32","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1185\/03007995.2015.1098598","volume":"31","author":"G Machnicki","year":"2015","unstructured":"Machnicki G, Ong SH, Chen W, Wei ZJ, Kahler KH. Comparison of amlodipine\/valsartan\/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs. Curr Med Res Opin. 2015;31:2287\u201396.","journal-title":"Curr Med Res Opin"},{"key":"127_CR33","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1527-5299.2003.03269.x","volume":"9","author":"AA Taylor","year":"2003","unstructured":"Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate\/benazepril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9:324\u201332.","journal-title":"Congest Heart Fail"},{"key":"127_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/hr.2015.142","volume":"39","author":"RC Hermida","year":"2016","unstructured":"Hermida RC, Ayala DE, Smolensky MH, Fern\u00e1ndez JR, Moj\u00f3n A, Portaluppi F. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks. Hypertens Res. 2016;39:277\u201392.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0127-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0127-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0127-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:19:42Z","timestamp":1684617582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-018-0127-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["127"],"URL":"https:\/\/doi.org\/10.1038\/s41440-018-0127-0","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"13 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TI, AO, SH, YS, and NN are current employees of Takeda Pharmaceutical Company Ltd. TT has received honoraria from Daiichi Sankyo Co. Ltd, MSD KK, Sanwa Kagaku Kenkyusho Co. Ltd, Shionogi & Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd, Takeda Pharmaceutical Company Ltd, and Teijin Pharma Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}